Developing therapies for advanced bladder cancer

Bibliography

• STERNBERG CN, YAGODA A, SCHERHI etal.: Methotrexate, vinblastine, doxorubicin, and cisplatin for advanced transitional cell carcinoma of the urothelium. Efficacy and patterns of response and relapse. Cancer (1989) 64:2448–2458.
   Google Scholar
• SEIDMAN AD, SCHER HI, GABRILOVE JL et al.: Dose-intensification of M-VAC with recombinant granulocyte colony-stimulating factor as initial therapy in advanced urothelial cancer. j. Clin. (1993) 11:408–414.
   Google Scholar
• STERNBERG CN, DE MULDER PH, VAN OOSTEROM AT et al.: Escalated M-VAC chemotherapy and recombinant human granulocyte-macrophage colony stimulating factor (rhGM-CSF) in patients with advanced urothelial tract tumors. Ann. amyl. (1993) 4: 403–407.
   Google Scholar
• LOEHRER PJSR., ELSON P DREICER Ret al.: Escalated dosages of methotrexate, vinblastine, doxorubicin, and cisplatin plus recombinant human granulocyte colony- stimulating factor in advanced urothelial carcinoma: an Eastern Cooperative Oncology Group trial. I Clin Oncol. (1994) 12:483–488.
   Google Scholar
• LOGOTHETIS CJ, FINN LD, SMITH T et al.: Escalated MVAC with or without recombinant human granulocyte-macrophage colony-stimulating factor for the initial treatment of advanced malignant urothelial tumors: results of a randomized trial. j Clin. Oncol. (1995) 13: 2272–2277.
   PubMed Web of Science ®Google Scholar
• STERNBERG CN, DE MULDER PH, SCHORNAGE, JH et al.: Randomized phase III trial of high-dose-intensity methotrexate, vinblastine, doxorubicin, and cisplatin (MVAC) chemotherapy and recombinant human granulocyte colony-stimulating factor versus classic MVAC in advanced urothelial tract tumors: European Organization for Research and Treatment of Cancer Protocol no. 30924. j. Clin. Oncol. (2001) 19:2638–2646.
   Google Scholar
• •Proved significance of high dose intensification of MVAC using GCSE
   Google Scholar
• Does neoadjuvant cisplatin-based chemotherapy improve the survival of patients with locally advanced bladder cancer: a meta-analysis of individual patient data from randomized clinical trials: advanced bladder cancer overview collaboration. Br. J. Urol. (1995) 75:206–213.
   PubMedGoogle Scholar
• Neoadjuvant cisplatin, methotrexate, andvinblastine chemotherapy for muscle-invasive bladder cancer: a randomized controlled trial. International collaboration of trialists. Lancet (1999) 354:533–540.
   PubMedGoogle Scholar
• •Proved significance of neoadjuvant MVAC for muscle-invasive bladder cancer.
   Google Scholar
• DODD PM, MCCAFFREY JA, HERR H et al.: Outcome of postchemotherapy surgery after treatment with methotrexate, vinblastine, doxorubicin, and cisplatin in patients with unresectable or metastatic transitional cell carcinoma. j. Clin. Oncol. (1999) 17:2546–2552.
   PubMed Web of Science ®Google Scholar
• NEWMAN L: Bladder cancer chemotherapy trial generates more questions than it answers. I Natl. Cancer Inst. (2001) 93:973–975
   PubMed Web of Science ®Google Scholar
• ROTH BJ, DREICER R, EINHORN LH et al.: Significant activity of paclitaxel in advanced transitional-cell carcinoma of the urothelium: a phase II trial of the eastern cooperative oncology group. I Clin. Oncol. (1994)12:2264–2270.
   PubMed Web of Science ®Google Scholar
• MCCAFFREY JA, HILTON S, MAZUMDAR M et al.: Phase II trial of docetaxel in patients with advanced or metastatic transitional-cell carcinoma. j. Oncol. (1997) 15:1853–1857.
   Web of Science ®Google Scholar
• VON DER MAASE H: Gemcitabine in locally advanced and/or metastatic bladder cancer. Grit. Rev Oncol. Hematol. (2000) 34:175–183
   PubMed Web of Science ®Google Scholar
• WITTE RS, ELSON P, BONO B et al: Eastern Cooperative Oncology Group phase II trial of ifosfamide in the treatment of previously treated advanced urothelial carcinoma. j. Clin. Oncol. (1997) 15:589–593.
   PubMed Web of Science ®Google Scholar
• BURCH PA, RICHARDSON RL, CHA SS et al.: Phase II trial of combination paclitaxel and cisplatin in advanced urothelial carcinoma (UC). Proc. Am. Soc. Oncol. (1999) 18(329a, abstr).
   Google Scholar
• DREICER R, MANOLA J, ROTH BJ etal.: Phase II study of cisplatin and paclitaxel in advanced carcinoma of the urothelium: an eastern cooperative oncology group study. J. CM]. Oncol. (2000) 18:1058–1061.
   Google Scholar
• VAUGHN DJ, MALKOWICZ SB, ZOLTICK B et al: Paclitaxel plus carboplatin in advanced carcinoma of the urothelium: an active and tolerable outpatient regimen. I Clin. Oncol (1998) 16:255–260.
   PubMed Web of Science ®Google Scholar
• PYCHA A, GRBOVIC M, POSCH B et al.: Paclitaxel and carboplatin in patients with metastatic transitional cell cancer of the urinary tract. Urology (1999) 53:510–515.
   PubMed Web of Science ®Google Scholar
• SENGELOV L, KAMBY C, LUND B et al.: Docetaxel and cisplatin in metastatic urothelial cancer: a phase II study. I Clin. Oncol. (1998) 16: 3392–3397.
   PubMed Web of Science ®Google Scholar
• GARCIA DEL MURO X, MARCUELLO E, CLIMENT MA et al: Phase II Study of Docetaxel and Cisplatin in Advanced Urothelial Cancer: Preliminary Results. Proc. Am. Soc. CM]. Oncol. (1999) 18: 339a (abstr.).
   Google Scholar
• VON DER MAASE H, ANDERSEN L, CRINO L et al.: Weekly gemcitabine and cisplatin combination therapy in patients with transitional cell carcinoma of the urothelium: a phase II clinical trial. Ann. Oncol. (1999) 10:1461–1465.
   Google Scholar
• KAUFMAN D, RAGHAVAN D, CARDUCCI M et al.: Phase II trial of gemcitabine plus cisplatin in patients with metastatic urothelial cancer. I Clin Oncol. (2000) 18:1921–1927.
   PubMed Web of Science ®Google Scholar
• MOORE MJ, WINQUIST EW, MURRAY N etal.: Gemcitabine plus cisplatin, an active regimen in advanced urothelial cancer: a phase II trial of the National Cancer Institute of Canada Clinical Trials Group. I Clin. Oncol. (1999) 17: 2876–2881.
   Google Scholar
• MELUCH AA, GRECO FA, BURRIS HA et al.: Gemcitabine and Paclitaxel in Combination for Advanced Transitional Cell Carcinoma (TCC) of the Urothelial Tract: A Trial of the Minnie Pearl Research Network. Proc. Am. Soc. Clin. Oncol. (1999)18: 347a (abstr.).
   Google Scholar
• HUSSAIN M, VAISHAMPAYAN U, DU W eta].: Combination paclitaxel, acrboplatin, and gemcitabine is an active treatment for advanced urothelial cancer. Oncol. (2001) 19:2527–2533.
   Google Scholar
• BAJORIN DE MCCAFFREY JA, DODD PM et al.: Ifosfamide, paclitaxel, and cisplatin for patients with advanced transitional cell carcinoma of the urothelial tract: final report of a phase II trial evaluating two dosing schedules. Cancer (2000) 88:1671–1678.
   PubMed Web of Science ®Google Scholar
• VON DER MAASE H, HANSEN SW, ROBERTS JT et al.: Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study. I Clin. Oncol. (2000) 18:3068–3077.
   Google Scholar
• •A Phase III trial of a new combination chemotherapy for advanced bladder cancer.
   Google Scholar
• BAJORIN DF: Exploring sequenced chemotherapy regimens in the treatment of transitional cell carcinoma of the urothelial tract. Eur. I Cancer (2000) 36\(Suppl. 2)26-
   Google Scholar
• PETRYLAK DP, SCHER HI, REUTER V et al.: P-glycoprotein expression in primary and metastatic transitional cell carcinoma of the bladder. Ann. Oncol. (1994) 5:835–840.
   PubMed Web of Science ®Google Scholar
• PENDYALA L, VELAGAPUDI S, TOTH K et al.: Translational studies of glutathione in bladder cancer cell lines and human specimens. CM]. Cancer Res. (1997) 3:793–798.
   PubMed Web of Science ®Google Scholar
• EDELMAN MJ, MEYERS FJ, MILLER TR et al.: Phase I/II study of paclitaxel, carboplatin, and methotrexate in advanced transitional cell carcinoma: a well-tolerated regimen with activity independent of p53 mutation. Urology (2000) 55:521–525.
   PubMed Web of Science ®Google Scholar
• HASEGAWA S, ABET, NAITO S et al: Expression of multidrug resistance-associated protein (MRP), MDR1 and DNA topoisomerase II in human multidrug-resistant bladder cancer cell lines. Br J. Cancer (1995) 71:907–913.
   PubMed Web of Science ®Google Scholar
• LIPPONEN P AND ESKELINEN M: Expression of epidermal growth factor receptor in bladder cancer as related to established prognostic factors, oncoprotein (c-erbB-2, p53) expression and long-term prognosis. Br j. Cancer (1994) 69:1120–1125.
   PubMed Web of Science ®Google Scholar
• JERIC LR, PEKMEZOVIC T, CVETKOVIC LP et al.: Concomitant radiotherapy and carboplatin in locally advanced bladder cancer. Eur. Ural. (1999) 36:401–405.
   PubMed Web of Science ®Google Scholar
• SHIPlEY WU, KAUFMAN DS, HENEY NM etal.: An update of combined modality therapy for patients with muscle invading bladder cancer using selective bladder preservation or cystectomy. j Ural. (1999) 62:445–450.
   Google Scholar
• •Indicates a possibility of bladder-preserving therapy for invasive bladder cancer.
   Google Scholar
• MIYANAGA N, AKAZA H, OKUMURA T et al.: A bladder preservation regimen using intra-arterial chemotherapy and radiotherapy for invasive bladder cancer: a prospective study. Int. j Ural. (2000) 7:41–48.
   PubMed Web of Science ®Google Scholar
• •Indicates a possibility of bladder-preserving therapy for invasive bladder cancer.
   Google Scholar